The Venture Codex

Led · Equity · Jun 2026

Mindmaze Therapeutics is a biotechnology company based in Lausanne. Public reporting around this financing describes the company entering a structured capital agreement with Neuro.io that includes both equity purchase and convertible debt. The firms are exploring a strategic rapprochement that could lead to a partnership or merger. Beyond the transaction details, the articles do not provide information on Mindmaze's products, revenues, user metrics, or founding year. Recent corporate activity is dominated by this two-tranche CHF 8 million deal with Neuro.io.